Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation
Glenn S. Van Aller(GlaxoSmithKline (United Kingdom)), Ryan G. Kruger(Arysta LifeScience (France)), Glòria Mas Martín(University of Miami), Shichong Liu(University of Pennsylvania), Roland S. Annan(GlaxoSmithKline (United Kingdom)), Benjamin A. Garcia(Washington University in St. Louis), Nicolas Reynoird(Centre National de la Recherche Scientifique), Robert H. Sinnamon(GlaxoSmithKline (United States)), Michael J. Huddleston(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Or Gozani(Stanford University), Julien Sage(Stanford University), Olena Barbash(GlaxoSmithKline (United States)), BaoChau Le(GlaxoSmithKline (United States)), Anne‐Flore Zmoos(University of California, Davis), Patrick McDevitt(GlaxoSmithKline (United States))
Cited by 174
Related Papers
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848